(Q39257653)

10 September 2017

title

Eribulin mesylate in heavily pretreated metastatic breast cancer patients: current practice in an Italian community hospital (English)

1 reference

10 September 2017

main subject

metastatic breast cancer

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24490609%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

author name string

Paola Poletti

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24490609%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Valentina Ghilardi

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24490609%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Laura Milesi

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24490609%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Elena Rota Caremoli

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24490609%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Carlo Tondini

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24490609%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

language of work or name

English

0 references

publication date

1 February 2014

1 reference

10 September 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24490609%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

volume

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24490609%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24490609%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

page(s)

233-239

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24490609%20AND%20SRC:MED&resulttype=core&format=json

Patterns of failure in a randomized trial of adjuvant chemotherapy in postmenopausal patients with early breast cancer treated with tamoxifen

3 June 2020

cites work

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.251

Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.251

Achievements in systemic therapies in the pregenomic era in metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.251

The European medicines agency review of eribulin for the treatment of patients with locally advanced or metastatic breast cancer: summary of the scientific assessment of the committee for medicinal products for human use.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.251

Novel anti-tubulin cytotoxic agents for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.251

A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.251

Phase I study of eribulin mesylate administered once every 21 days in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.251

Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.251

Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.251

A phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.251

Eribulin mesylate for the treatment of patients with refractory metastatic breast cancer: use of a "physician's choice" control arm in a randomized approval trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.251

Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.251

Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.251

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.251

21 January 2018

Identifiers

DOI

10.2217/FON.13.251

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24490609%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

1 reference